Dec 23, 2024 · REGEN-COV also remains authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of...

Learn how Regeneron is actively working on testing existing medicines and developing new antibodies to combat the COVID-19 pandemic.

Aug 19, 2021 · The US Food and Drug Administration gave an emergency use authorization to a treatment made by Regeneron called casirivimab and imdevimab, and another made by GlaxoSmithKline called sotrovimab....

Aug 19, 2021 · In the state-run treatment centers, the monoclonal antibody treatment is free and available without a prescription or referral by a healthcare provider.

time, to use REGEN-COV for the treatment of mild to moderate COVID-19 or as post-exposure prophylaxis for COVID-19 in the United States. All formulations and presentations of casirivimab and imdevimab or REGEN-COV

Apr 12, 2021 · Regeneron will seek U.S. approval for its Covid-19 antibody cocktail as a preventative treatment after a trial showed it helped reduce the risk of symptomatic infections in households where...

First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2. Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients.

Sep 29, 2020 · Regeneron's monoclonal antibody two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized patients with mild-to-moderate Covid.

Jan 26, 2021 · Drugmaker Regeneron's monoclonal antibody cocktail is effective in preventing Covid-19, according to a study released by the company. The antibody cocktail is authorized by the FDA as a...

Nov 22, 2020 · US officials have granted emergency authorisation for an experimental antibody treatment given to President Trump after his Covid-19 diagnosis. The drug, developed by Regeneron, will be...